Search

Your search keyword '"Negrean-Dzyuba C"' showing total 2 results
Start Over Author "Negrean-Dzyuba C"
2 results on '"Negrean-Dzyuba C"'

1. Adherence to guideline recommendations for multimodality treatment of patients with pT2–3 M0 non‐urothelial carcinoma of the urinary bladder: Temporal trends and survival outcomes

Author

Shahrokh F. Shariat, Emanuele Montanari, Pierre I. Karakiewicz, Zhe Tian, Alberto Briganti, Fred Saad, Ottavio De Cobelli, Sophie Knipper, Carlotta Palumbo, Francesco A. Mistretta, Paul Perrotte, Gennaro Musi, Angela Pecoraro, Cristina Negrean-Dzyuba, Mistretta, F. A., Negrean-Dzyuba, C., Palumbo, C., Pecoraro, A., Knipper, S., Tian, Z., Musi, G., Montanari, E., Perrotte, P., Briganti, A., Shariat, S. F., Saad, F., de Cobelli, O., and Karakiewicz, P. I.

Subjects
squamous cell carcinoma, medicine.medical_specialty, combined modality therapy, Urology, medicine.medical_treatment, 030232 urology & nephrology, Kaplan-Meier Estimate, Cystectomy, 03 medical and health sciences, 0302 clinical medicine, Carcinoma, medicine, Humans, Neoplasm Staging, Retrospective Studies, Carcinoma, Transitional Cell, adenocarcinoma, Urinary bladder, Proportional hazards model, business.industry, Mortality rate, Hazard ratio, neuroendocrine carcinoma, medicine.disease, Combined Modality Therapy, Radiation therapy, medicine.anatomical_structure, Urinary Bladder Neoplasms, 030220 oncology & carcinogenesis, Adenocarcinoma, urinary bladder neoplasms, business
Abstract

Objectives: To analyze contemporary multimodality treatment rates, defined as radical cystectomy plus chemotherapy and/or radiotherapy, for pT2–3 any N-stage M0 non-urothelial carcinoma of urinary bladder patients. Additionally, we tested for the effect of multimodality treatment versus radical cystectomy alone on cancer-specific mortality. Methods: Within the Surveillance, Epidemiology and End Results database (2004–2015), 887 pT2–3 any N-stage M0 non-urothelial carcinoma of urinary bladder patients treated with radical cystectomy were identified. Kaplan–Meier plots, and univariable and multivariable Cox regression analyses focused on cancer-specific mortality rates. Results: Squamous cell carcinoma was recorded in 499 (56.3%) patients, neuroendocrine carcinoma in 246 (27.7%) and adenocarcinoma in 142 (16.0%). The highest proportion of multimodality treatment patients was recorded in neuroendocrine carcinoma (69.1%), relative to adenocarcinoma (34.5%) and squamous cell carcinoma (26.4%). A statistically significant annual increase was recorded in multimodality treatment rates in neuroendocrine carcinoma patients (46.7–74.2%, P&nbsp

Published
2020
Full Text
View/download PDF

2. Adherence to guideline recommendations for multimodality treatment of patients with pT2-3 M0 non-urothelial carcinoma of the urinary bladder: Temporal trends and survival outcomes.

Author

Mistretta FA, Negrean-Dzyuba C, Palumbo C, Pecoraro A, Knipper S, Tian Z, Musi G, Montanari E, Perrotte P, Briganti A, Shariat SF, Saad F, de Cobelli O, and Karakiewicz PI

Subjects
Combined Modality Therapy, Cystectomy, Humans, Kaplan-Meier Estimate, Neoplasm Staging, Retrospective Studies, Carcinoma, Transitional Cell pathology, Urinary Bladder Neoplasms surgery
Abstract

Objectives: To analyze contemporary multimodality treatment rates, defined as radical cystectomy plus chemotherapy and/or radiotherapy, for pT2-3 any N-stage M0 non-urothelial carcinoma of urinary bladder patients. Additionally, we tested for the effect of multimodality treatment versus radical cystectomy alone on cancer-specific mortality., Methods: Within the Surveillance, Epidemiology and End Results database (2004-2015), 887 pT2-3 any N-stage M0 non-urothelial carcinoma of urinary bladder patients treated with radical cystectomy were identified. Kaplan-Meier plots, and univariable and multivariable Cox regression analyses focused on cancer-specific mortality rates., Results: Squamous cell carcinoma was recorded in 499 (56.3%) patients, neuroendocrine carcinoma in 246 (27.7%) and adenocarcinoma in 142 (16.0%). The highest proportion of multimodality treatment patients was recorded in neuroendocrine carcinoma (69.1%), relative to adenocarcinoma (34.5%) and squamous cell carcinoma (26.4%). A statistically significant annual increase was recorded in multimodality treatment rates in neuroendocrine carcinoma patients (46.7-74.2%, P < 0.01), but not in adenocarcinoma or squamous cell carcinoma patients. The 5-year cancer-specific mortality rate in neuroendocrine carcinoma patients was significantly lower after multimodality treatment versus radical cystectomy alone (37.0% vs 51.5%; P < 0.01), but no statistically significant differences were recorded in both adenocarcinoma (46.1% vs 35.5%; P = 0.8) and squamous cell carcinoma (41.4% vs 31.1%; P = 0.8) patients. In multivariable analyses, for neuroendocrine carcinoma patients, multimodality treatment was an independent predictor of a lower cancer-specific mortality rate (hazard ratio 0.58, P = 0.03)., Conclusions: Multimodality treatment has been increasingly used during the study period in neuroendocrine carcinoma patients, and it has translated into a cancer-specific mortality benefit. This is not the case for other non-urothelial carcinoma of urinary bladder patients, such as adenocarcinoma or squamous cell carcinoma., (© 2020 The Japanese Urological Association.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results